California · Nonprofit
Scleroderma Research Foundation
Scleroderma Research Foundation (California) receives grants from 103 organizations whose IRS filings report $8,801,292 to it, the largest being KAO FAMILY FOUNDATION ($2,590,000). 50 of them have funded it in more than one year, and 53% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2025
- $13M
- Funders on record
- 103
- Grants received
- $8.8M
- Net assets
- $17M
What Scleroderma Research Foundation does
Mission
The mission of the Scleroderma Research Foundation is to fund and facilitate the most promising, highest quality research aimed at new treatments and, ultimately, a cure for scleroderma.
As stated on its FY2025 Form 990.
Programs
CONQUEST is a global, perpetual, clinical trial platform developed by the SRF in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma. CONQUEST is designed to rapidly advance promising treatments for scleroderma and to identify those agents that should progress from phase 2b to phase 3 clinical trials. CONQUEST will make an enduring contribution to the scleroderma community by creating an ecosystem designed to enable rapid and efficient development of novel drugs for scleroderma patients.
$4,446,116 spent47% of program spendingThe mission of the Scleroderma Research Foundation (SRF) is to find, fund, and facilitate the most promising, highest-quality research to cure scleroderma. We recruit the best and the brightest researchers to understand the causes, discover treatments, and ultimately eradicate this disease . At the SRF, research is at the center of all we do. Our Research Program is governed by the Board of Directors and supported by a volunteer Scientific Advisory Board comprised of some of the world's most highly regarded scientists who are leaders in their field of expertise. The Board of Directors and Scientific Advisors meet annually with researchers and clinicians from laboratories across the nation to select and fund the most promising scleroderma studies aimed at developing improved therapies to help patients live longer, fuller lives - and, ultimately, to find a cure for scleroderma.
$4,314,557 spentof which $3,733,185 as grants$5,907,254 earned by the program46% of program spendingSRF Education & Awareness Program: Many patients hear the word scleroderma for the first time when they are diagnosed. We strive to raise awareness and provide educational resources because lack of awareness about scleroderma often causes delays in treatment or misdiagnosis. As an innovator in scleroderma research, the SRF is uniquely qualified to provide those living with this disease, the medical community, and the general public with the most up-to-date, trusted and relevant news and information about complications, treatments, and related research through our website, webinars, annual patient forum, and monthly eNewsletter. And we deliver stories of impact that connect and inspire patients, as well as address issues related to diversity, equity, and inclusion that patients may encounter as they navigate diagnosis, treatment, and living with the disease.
$639,412 spent7% of program spendingThe SRF Research Program: Led by a Scientific Advisory Board comprised of some of the most highly regarded scientists in the nation, the SRFs research program actively seeks out and recruits experts from the fields of rheumatology, immunology, genetics, and fibrosis, as well as, experts in cutting-edge technologies to join the scleroderma research community. With an intense focus on identifying projects and investigators likely to move scleroderma research forward, the SRF funds a diverse portfolio of projects led by top-tier investigators.
The 4 programs described on its FY2025 Form 990, listed largest first by expense. Program spending in total: $9,400,085.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2023 to 2024, from $19M to $33M (+77%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2021 2%. Grants only. Government contracts and fees sit inside program revenue.
44% of Scleroderma Research Foundation’s revenue is contributions — more reliant on donations than three-quarters of its peers (7% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 0 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Board chair
Luke Evnin PhD
Chairman
As listed on its FY2025 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 31 funders to 40 funders, grant income rose $653k → $992k.
28 of 103 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 53% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of Scleroderma Research Foundation’s funders (the co-funder graph). Top 30 of 103 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
Scleroderma Research Foundation leans on a few funders — its largest provides 29% of grant income and the top three 64%; half comes from just 2 funders.
the vertical line marks half of all grant income — 2 funders to its left
54% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund Scleroderma Research Foundation.
Largest funder’s share by year: 2017 41% · 2018 79% · 2019 36% · 2020 61% · 2021 30% · 2022 37% · 2023 32% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
38% of Scleroderma Research Foundation's funders are still giving 3 years after their first grant; 49% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
53% of Scleroderma Research Foundation's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $4.1M that is directly attributable, 77% of it comes from funders outside California, across 21 states.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $4.7M arriving through sponsors registered in 17 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
Scleroderma Research Foundation runs a healthier operating margin than three-quarters of the 2,969 health nonprofits its size.
this organization peer median middle 50% of peers· 2,969 health nonprofits $10M–$100M, FY2025
Organizations like Scleroderma Research Foundation
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In California
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
91% of spending goes to programs.
Governance
Public support
70%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 1 state
Screen this organization
A dated, signed PDF of the compliance screen for Scleroderma Research Foundation: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds Scleroderma Research Foundation?
- Scleroderma Research Foundation (California) receives grants from 103 organizations whose IRS filings report $8,801,292 to it, the largest being KAO FAMILY FOUNDATION ($2,590,000). 50 of them have funded it in more than one year, and 53% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does Scleroderma Research Foundation have?
- IRS filings report 103 organizations giving $8,801,292 in grants to Scleroderma Research Foundation, 50 of which have funded it in more than one year.
- Who is the largest funder of Scleroderma Research Foundation?
- KAO FAMILY FOUNDATION is the largest funder on record, with $2,590,000 in grants. The full list of funders is on this page.
- How can an organization like Scleroderma Research Foundation find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in California. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 103 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing